Prevalence of obesity and its association with cardiometabolic risk factors, heart failure phenotype and mortality among patients hospitalized for heart failure in Egypt

Ahmed Hassanin1*, Mahmoud Hassanein2, Gregg M. Lanier1, Mohamed Sadaka3, Mohamed Rifaat3 and Mohamed Sanhoury2

Abstract

Background: Obesity is an established risk factor for cardiometabolic disease and heart failure (HF). Nevertheless, the relationship between obesity and HF mortality remains controversial.

Results: The goal of this study was to describe the prevalence of obesity in patients hospitalized for HF in Egypt and investigate the relationship of obesity to cardiometabolic risk factors, HF phenotype and mortality. Between 2011 and 2014, 1661 patients hospitalized for HF across Egypt were enrolled as part of the European Society of Cardiology HF Long-term Registry. Obese patients, defined by a BMI $\geq 30$ kg/m$^2$, were compared to non-obese patients. Factors associated with mortality on univariate analysis were entered into a logistic regression model to identify whether obesity was an independent predictor of mortality during hospitalization and at one-year follow-up. The prevalence of obesity was 46.5% and was higher in females compared to males. Obese as compared to non-obese patients had a higher prevalence of diabetes mellitus (47.0% vs 40.2%, $p = 0.031$), hypertension (51.3% vs 33.0%, $p < 0.001$) and history of myocardial infarction (69.2% vs 62.8%, $p = 0.005$). Obese patients as compared to non-obese patient were more likely to have acute coronary syndrome on admission (24.8% vs 14.2%, $p < 0.001$). The dominant HF phenotype in obese and non-obese patients was HF with reduced ejection fraction (EF); however, obese patients as compared to non-obese patient had higher prevalence of HF with preserved EF (22.3% vs 12.4%, $p < 0.001$). Multivariable analysis demonstrated that obesity was associated with an independent survival benefit during hospitalization, (OR for mortality 0.52 [95% CI 0.29–0.92]). Every point increase in BMI was associated with an OR $= 0.93$ [95% CI 0.89–0.98] for mortality during hospitalization. The survival benefit was not maintained at one-year follow-up.

Conclusions: Obesity was highly prevalent among the study cohort and was associated with higher prevalence of cardiometabolic risk factors as compared to non-obese patients. Obesity was associated with an independent “protective effect” from in-hospital mortality but was not a predictor of mortality at 1-year follow-up.

Keywords: Egypt, Obesity, Heart failure, Co-morbidities, Mortality

Background

Heart failure (HF) is a major global health challenge that is increasing in scope and severity in many countries [1–5]. Despite recent therapeutic advances, HF morbidity and mortality remain high. Similarly, obesity, defined as body mass index (BMI) over 25 kg/m$^2$, is a global public health problem.
health problem with over 2.2 billion people meeting the definition of overweight or obese in 2015 [6]. Obesity is a major risk factor for ischemic heart disease, which in turn is the most common etiology for HF with reduced ejection fraction (HFrEF). Additionally, obesity is strongly associated with left ventricular diastolic dysfunction and HF with preserved ejection fraction (HFpEF).

Accordingly, primary prevention of cardiometabolic syndrome and mitigation of established cardiovascular risk factors, which encompasses obesity, is an important component of standard HF management. However, the relationship between obesity and HF mortality has been controversial, with several large studies suggesting a “protective effect” of obesity in HF patients [7–9]. The data on this relationship has been largely confined to patients’ cohorts from western countries. In this analysis of a large cohort of patients admitted with decompensated HF in Egypt, we investigated the prevalence of obesity and its association with cardiometabolic risk factors, HF phenotype and mortality.

Methods
This study utilizes data from the Egyptian cohort of European Society of Cardiology (ESC) Heart Failure Long-term (ESC-HF-LT) Registry, which has been reported in detail elsewhere [10, 11]. Briefly, this is a multi-center, observational registry of patients from European and Mediterranean countries which are members of the ESC. Twenty medical centers across Egypt participated in this registry. The enrolling centers were chosen to truly reflect the heterogeneity and the Egyptian health care system and patient population. Between April 2011 and September 2014, 1661 patients hospitalized for decompensated HF in Egypt were enrolled, including patients with pre-existing or new diagnosis of HF. The diagnosis of HF was determined according to the clinical judgement of participating centers’ treating cardiologist. There were no exclusion criteria for this registry; however, all patients had to be adults in order to consent for participation in this study. The registry was approved by the institutional review board of the enrolling centers and in compliance with the Declaration of Helsinki.

Patients were classified into 5 categories according to body BMI: underweight (BMI < 18.5 kg/m²), normal body weight (BMI: 18.5–24.9 kg/m²), overweight (BMI: 25–29.9 kg/m²), obese (BMI: 30–39.9 kg/m²) and morbidly obese (BMI ≥ 40 kg/m²). For the purpose of this analysis, obese and morbidly obese patients were categorized as “obese”, while underweight, lean and overweight were categorized as non-obese. Chronic kidney disease (CKD) was defined as a serum creatinine > 1.5 mg/dl and anemia was defined as a hemoglobin ≤ 12 mg/dl. Continuous variables were expressed as mean with standard deviation, while categorical variables were represented as frequencies and rates. For categorical variables, the difference between obese and non-obese was analyzed using chi-square test. Unpaired t-test was used to compare continuous variables between obesity classes. Variables with P values < 0.05 on univariate analysis were introduced in the multivariable logistic regression model. Odds ratio (OR) was calculated for factors that were found to be independently associated with mortality. All tests were two sided and a P value of < 0.05 was considered significant. All analyses were done using SPSS for windows, version 21 (SPSS, Inc., Chicago, IL, USA).

Results
Between April 2011 and September 2014, 1661 patients hospitalized with HF were recruited by the enrolling centers across Egypt. A total of 53 patients were excluded due to missing BMI data, leaving 1608 patients who were eligible for analysis. Two thirds of the participants were males and one third were females.

Figure 1 demonstrates that the nearly half of the patients (46.5%) were either obese or morbidly obese. Females were more likely to be either obese or morbidly obese as compared to males (61.2% vs 39.7%). The differences in baseline characteristics between obese and non-obese patients are depicted in Table 1. Obese patients had a higher systolic blood pressure (SBP) on presentation (142.4 ± 33.6 vs 123.8 ± 27.5, P < 0.001) and higher heart rate (106.9 ± 23.6 vs 99.8 ± 19.6, P < 0.001) and were more likely to have acute coronary syndrome on admission (24.8% vs 14.2%, P < 0.001). Obese patient had greater prevalence of diabetes mellitus (47.0% vs 40.2%, P = 0.031), hypertension (51.3% vs 33.0%, P < 0.001), and history of myocardial infarction (69.2% vs 62.8%, P = 0.005). Non-obese patients were more likely to be smokers (68.5% vs 49.9%, P < 0.001) and have history of hepatic dysfunction (12.7% vs 5.9%, P < 0.001). Although the dominant phenotype of HF in obese and non-obese patients was HFrEF, the prevalence of both HFpEF and HF with mid-range ejection fraction (HFrEF) were significantly higher in obese patients, 22.3% versus 12.4%, P < 0.001 and 19.1% versus 15.1%, P < 0.001, respectively.

Table 2 illustrates differences between obese HF patients according to sex. The prevalence of obesity was significantly higher in females compared to males (61.3% vs 39.7%, P < 0.001). As compared to obese men, obese women were older (61.6 ± 10.9 vs 59.8 ± 10.5, P = 0.12) and had a higher prevalence of hypertension (57.5% vs 52.1%, P = 0.005), diabetes (52.1% vs 43.3%, P = 0.06) and anemia (87.2% vs 58.4%, P < 0.001). Obese women also presented with a higher left ventricular (LV) ejection fraction (43.5 ± 13.4 vs 38.8 ± 11.6, P < 0.001). HFpEF (LV ejection fraction > 50%) was
present in 31.9% of obese women versus 15.1% of obese men ($P < 0.001$). Atrial fibrillation was significantly more prevalent in obese women (34.4% vs 22.5% $P < 0.001$).

Table 3 demonstrates that in-hospital mortality was higher in non-obese patients compared to obese patients (7.6% vs 2.9%, $P < 0.001$), particularly in non-obese men. This difference in mortality between non-obese and obese patients was not seen at 1 year follow-up (28.0% vs 25.7%, $P = 0.41$).

Table 4 demonstrates the factors associated with survival at hospital discharge. On univariate analysis, obesity (OR 2.85, 95% CI [1.68–4.7]), a higher admission SBP (1.58, 95% CI [1.43–1.79], for every 10 points increase), and history of myocardial infarction (OR 1.75, 95% CI [1.11–2.74]) were associated with improved survival; while CKD (OR 0.31, 95% CI [0.19–0.50]) was associated with lower survival. Multivariable analysis, adjusted for age, sex, obesity, SBP, and history of myocardial infarction, confirmed that obesity was associated with an independent survival benefit during the in-hospital course (OR 1.92, 95% CI [1.10–3.44]). Every point increase in BMI was associated with an OR of 0.93 (95% CI 0.89–0.98) for mortality. At one-year follow-up, obesity was not associated with mortality on univariate or multivariable analysis. Age, LV ejection fraction, CKD and anemia were associated with survival on both univariate and multivariable analysis (Table 5).

**Discussion**

The main findings of this study:

1. Obesity was highly prevalent among patients admitted for decompensated HF in Egypt: 39.7% of males and 61.2% of females were either obese or morbidly obese.
2. Among obese patients, hypertension, diabetes, and anemia were more common as compared to non-obese patients.
3. Among obese patients, HFpEF prevalence was nearly double that of non-obese patients.
4. Obesity was associated with a “protective effect” from in-hospital mortality, but this effect was absent at 1-year follow-up.

**Prevalence of obesity in Egypt**

The Global Burden of Disease 2015 Obesity Collaborators study reported that among the 20 most populous countries, the highest level of age-standardized adult obesity was observed in Egypt (35.3%, 95% CI [33.6 to 37.1]) [6]. The Demographic and Health Survey (DHS) conducted in Egypt in 2015 reported that prevalence of obesity among adult women was double that of men, 50.3% versus 26.4% [12]. The prevalence of obesity in women was higher than men across all age brackets, with the peak
prevalence of obesity in women observed in both sexes in the 55–59 years age group. Obesity in Egyptian women correlated with age, from less than 10% among adolescent women to over 65% in women aged 55–59 years. In large survey conducted in Cairo in 2007, Egypt's largest city, obesity was prevalent across all strata of socioeconomic classes [13]. Further analysis of the DHS 2008 data demonstrated that in women with the low educational attainment but high economic means had the highest prevalence of obesity [14].

In the ESC-HF-LT Registry, the median BMI of patients hospitalized for HF in Egypt was 29.4 kg/m² (IQR:26.5–33.2) as compared to 27.7 kg/m² (IQR: 24.2–31.2) [9] in their European counterparts, but was similar to that reported in the HEARTS registry carried out in Saudi Arabia (29.2 kg/m² ± 6.7) [13]. The obesity epidemic in Egypt is reflective of a wider regional problem seen in the World Health Organization (WHO) Eastern Mediterranean Region, in which half of all women and more than two in five men were overweight or obese [15].

**Table 1** Baseline characteristics among obese and non-obese patients with heart failure

|                                | Obese (n = 750) | Non-obese (n = 853) | P value |
|--------------------------------|-----------------|---------------------|---------|
| **Age (years)**                | 60.59 ± 10.7    | 59.58 ± 13.9        | 0.117   |
| **Male**                       | 58.0 (435)      | 75.9 (647)          | <0.001  |
| **Presentation**               |                 |                     |         |
| SBP (mmHg)                     | 142.41 ± 33.6   | 123.82 ± 27.5       | <0.001  |
| HR (beat/min)                  | 106.96 ± 23.6   | 99.89 ± 19.6        | <0.001  |
| NYHA class                     |                 |                     |         |
| III                            | 59.3 (416)      | 61.2 (417)          | 0.48    |
| IV                             | 40.7 (286)      | 38.8 (264)          |         |
| **Hospital presentation**      |                 |                     |         |
| ACS/HF                         | 24.8 (188)      | 14.2 (106)          | <0.001  |
| Cardiogenic shock              | 2.1 (16)        | 5.6 (42)            |         |
| Decompensated HF               | 46.1 (345)      | 62.9 (470)          |         |
| Hypertensive HF                | 8 (59)          | 2 (15)              |         |
| Pulmonary edema                | 14.8 (111)      | 9.9 (74)            |         |
| Right HF                       | 4.1 (30)        | 5.4 (40)            |         |
| **HF etiology and cardiac evaluation** |                 |                     |         |
| Primary etiology               |                 |                     |         |
| DCM                            | 14.1 (104)      | 19.7 (144)          | <0.001  |
| HTN                            | 6.3 (46)        | 2.2 (16)            |         |
| Ischemic                       | 68.6 (505)      | 62.1 (454)          |         |
| Valve disease                  | 7.3 (54)        | 10 (73)             |         |
| Other                          | 3.7 (27)        | 6 (44)              |         |
| **EF (%)**                     | 40.89 ± 12.6    | 36.7 ± 11.7         | <0.001  |
| EF < 40                        | 58.6 (346)      | 72.5 (375)          | <0.001  |
| 40–49                          | 19.1 (113)      | 15.1 (78)           |         |
| ≥ 50                           | 22.3 (132)      | 12.4 (67)           |         |
| **Comorbidities**              |                 |                     |         |
| History of MI                  | 69.2 (519)      | 62.8 (470)          | 0.005   |
| Smoking                        | 49.9 (750)      | 68.5 (749)          | <0.001  |
| Diabetes                       | 47.0 (352)      | 40.2 (312)          | 0.031   |
| HTN                            | 51.3 (385)      | 33.0 (247)          | <0.001  |
| AF                             | 27.4 (196)      | 25.4 (179)          | 0.22    |
| CKD                            | 17.2 (129)      | 16.2 (121)          | 0.628   |
| COPD                           | 12.4 (93)       | 14.6 (109)          | 0.227   |
| Stroke                         | 6.7 (50)        | 8.7 (65)            | 0.147   |
| PVD                            | 5.3 (40)        | 4.8 (36)            | 0.724   |
| Hepatic dysfunction            | 5.9 (44)        | 12.7 (95)           | <0.001  |
| Anemia                         | 70.8 (402)      | 62.5 (408)          | 0.001   |

Values are n (%) or mean (± SD)

ACS: acute coronary syndrome; AF: Atrial fibrillation; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; EF: Ejection fraction; HR: Heart rate; HF: heart failure; HTN: Hypertension; MI: Myocardial infarction; NYHA: New York Heart Association; PVD: Peripheral vascular disease; SBP: Systolic blood pressure
Table 2  Baseline characteristics among obese men and obese women with heart failure

|                                | Obese Men \(n = 435\) | Obese Women \(n = 315\) | \(P\) value |
|--------------------------------|-------------------------|--------------------------|-------------|
| **Age (years)**                | 59.8 ± 10.5             | 61.6 ± 10.9              | 0.117       |
| **Presentation**               |                         |                          |             |
| SBP (mmHg)                     | 139.7 ± 31.3            | 146.1 ± 36.2             | 0.01        |
| HR (beat/min)                  | 105.6 ± 21.7            | 108.7 ± 25.9             | 0.073       |
| NYHA class                     |                          |                          |             |
| III                            | 60.7 (246)              | 57.4 (171)               | 0.39        |
| IV                             | 39.3 (149)              | 42.6 (127)               |             |
| **Hospital presentation**      |                         |                          |             |
| ACS/HF                         | 283 (123)               | 20.1 (63)                | 0.21        |
| Cardiogenic shock              | 1.1 (43)                | 3.5 (11)                 |             |
| Decompensated HF               | 47.6 (207)              | 43.9 (138)               |             |
| Hypertensive HF                | 6 (26)                  | 10.8 (34)                |             |
| Pulmonary edema                | 14.5 (63)               | 15.3 (48)                |             |
| Right HF                       | 2.5 (11)                | 6.4 (20)                 |             |
| **Cardiac evaluation**         |                         |                          |             |
| EF (%)                         | 38.8 ± 11.6             | 43.5 ± 13.4              | <0.001      |
| EF < 40                        | 64.8 (219)              | 50.4 (128)               | <0.001      |
| EF 40–49                       | 20.1 (68)               | 17.7 (43)                |             |
| EF ≥ 50                        | 15.1 (51)               | 31.9 (81)                |             |
| **Primary etiology**           |                         |                          |             |
| DCM                            | 14.8 (63)               | 13.2 (41)                | 0.46        |
| HTN                            | 4.9 (21)                | 8 (25)                   |             |
| Ischemic                       | 69.6 (296)              | 67.2 (209)               |             |
| Valve disease                  | 6.8 (29)                | 8 (25)                   |             |
| Other                          | 3.8 (16)                | 3.5 (11)                 |             |
| **Comorbidities**              |                         |                          |             |
| History of MI                  | 74.9 (326)              | 61.3 (193)               | <0.001      |
| Smoking                        | 80 (348)                | 8.3 (26)                 | <0.001      |
| Diabetes                       | 43.3 (187)              | 52.1 (163)               | 0.006       |
| HTN                            | 52.1 (204)              | 57.5 (181)               | 0.005       |
| AF                             | 22.5 (95)               | 34.4 (101)               | 0.001       |
| CKD                            | 15.2 (66)               | 20.0 (63)                | 0.09        |
| COPD                           | 16.3 (71)               | 7.0 (22)                 | 0.001       |
| Stroke                         | 5.5 (24)                | 8.2 (26)                 | 0.141       |
| PVD                            | 5.7 (25)                | 4.8 (15)                 | 0.62        |
| Hepatic dysfunction            | 6.7 (29)                | 4.8 (15)                 | <0.001      |
| Anemia                         | 58.4 (198)              | 87.2 (224)               | <0.001      |

Values are n (%) or mean (± SD)

ACS: acute coronary syndrome; AF: Atrial fibrillation; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; EF: Ejection fraction; HR: Heart rate; HF: heart failure; HTN: Hypertension; MI: Myocardial infarction; NYHA: New York Heart Association; PVD: Peripheral vascular disease; SBP: Systolic blood pressure

Table 3  In-hospital and one-year mortality for the entire cohort and among obese and non-obese men and women with heart failure

| Mortality | Entire cohort | Men | Women |
|-----------|--------------|-----|-------|
|           | Obese | Non-obese | \(P\) value | Obese | Non-obese | \(P\) value | Obese | Non-obese | \(P\) value |
| In-hospital | 2.9 (21) | 7.6 (56) | <0.001 | 1.6 (7) | 7.3 (42) | <0.001 | 4.6 (14) | 8.8 (14) | 0.06 |
| 1 year    | 25.7 (152) | 28.0 (149) | 0.41 | 24.2 (83) | 26.9 (115) | 0.408 | 27.7 (69) | 32.1 (34) | 0.24 |

Values are n (%) or mean (± SD)
Obesity, cardiometabolic disease risk factors and cardiovascular disease: Diabetes mellitus: Obesity was associated with significantly higher prevalence of diabetes mellitus type 2 in this study. Diabetes was more prevalent in obese women versus obese men (52.1% vs 43.3%, \( \text{P} = 0.006 \)). Egypt is among the top 10 countries in the world with the number of adults with diabetes in 2013, with a prevalence rate of 15.5\% [16]. Obesity, especially visceral adiposity, and physical inactivity are major risk factors for diabetes in Egypt. It is hypothesized that adipose tissue and insulin resistance may produce a systemic proinflammatory state modulated through cytokines production that leads to myocyte remodeling and the development of HFpEF [17, 18].

Hypertension
The prevalence of hypertension in the Egyptian cohort was 43.5\% as compared to 64.5\% in the European cohort of the ESC-HF-LT registry [10]. Prevalence of hypertension was higher in obese patients regardless of sex. Obese women had the highest prevalence of hypertension (57.5\%). The reported prevalence of hypertension (defined as a blood pressure \( > 140/90 \)) in the Egypt STEPwise survey conducted in 2017 was 29.9\% for adult men and 29.2\% for women [19], in comparison to the reported prevalence in the National Hypertension Project (NHP), conducted 15 years earlier, of 25.7\% in men and 26.9\% in women. The NHP found that 50\% of the surveyed individuals had central obesity. Increasing adiposity was associated with enhanced renin angiotensin aldosterone system stimulation and sympathetic system over activation which cause increased arterial stiffness, hypertension and cardiac diastolic dysfunction [20].

Anemia
Anemia was highly prevalent in our heart failure population, ironically more in the obese than non-obese patients. In a meta-analysis by Groenveld et al. of 34 studies, comprising 153,180 patients with HF, anemia was associated with an increased risk of mortality in both HFrEF and HFpEF [21]. Anemia can occur in heart failure with or without chronic kidney disease and is likely to be due to increased production of tumor necrosis factor-alpha and interleukin-6, which in turn can cause reduced erythropoietin secretion. The anemia can cause progressive worsening of cardiac function by increasing cardiac demand and LV hypertrophy, which in turn can lead to myocyte apoptosis.

### Table 4 Factors associated with survival at hospital discharge

| Clinical variable | Univariate analysis | Multivariable analysis |
|-------------------|---------------------|------------------------|
|                   | OR  | 95\% CI | P value | OR  | 95\% CI | P value |
| Obesity           | 2.85 | 1.68–4.7 | <0.0001 | 1.92 | 1.1–3.44 | 0.026 |
| SBP \( ^{\text{a}} \) | 1.58 | 1.43–1.79 | <0.0001 | 1.67 | 1.35–1.85 | >0.001 |
| History of MI     | 1.75 | 1.11–2.74 | 0.01 | -- | -- | -- |
| CKD               | 0.312 | 0.19–0.50 | <0.001 | 0.32 | 0.15–0.66 | 0.002 |

CKD: chronic kidney disease; SBP: Systolic blood pressure; MI: Myocardial infarction

\( ^{\text{a}} \) SBP—for every 10 point increase

### Table 5 Factors associated with survival at one-year follow-up

| Clinical variable | Univariate analysis | Multivariable analysis |
|-------------------|---------------------|------------------------|
|                   | OR   | 95\% CI | P value | OR   | 95\% CI | P value |
| Obesity\( ^{\text{a}} \) | -- | -- | -- | -- | -- | -- |
| Age\( ^{\text{a}} \) | 1.72 | 1.56–1.96 | <0.0001 | 1.47 | 1.25–1.56 | <0.0001 |
| EF \( ^{\text{~}} \) | 1.32 | 1.22–1.40 | <0.0001 | 1.52 | 1.37–1.69 | <0.0001 |
| CKD               | 0.49 | 0.37–0.62 | <0.0001 | 0.55 | 0.31–0.94 | 0.03 |
| Anemia            | 0.625 | 0.46–0.84 | <0.0001 | 0.59 | 0.38–0.9 | 0.02 |

EF: Ejection fraction; CKD: chronic kidney disease

\( ^{\text{a}} \) Obesity was not association with survival at one-year follow-up

\( ^{\text{a}} \) Age for every 10 years below 75

\( ^{\text{~}} \) Ejection Fraction—for every 5% increase above 25%
**Ischemic heart disease**

Ischemia was the dominant underlying etiology of HF in the majority of patients in this registry and it was more frequent in obese patients. Moreover, acute coronary syndrome on presentation was more common in obese patients. In a large meta-analysis of 302,000 persons, overweight and obesity were independently associated with developing coronary artery disease, RR to 1.17 (1.11–1.23), independent of hypertension and dyslipidemia [22].

**Atrial fibrillation**

Prevalence of atrial fibrillation (AF) in the Egyptian cohort was significantly lower than other European countries participating in the ESC-HF-LT registry (24.3% vs 48.4%, \( P < 0.0001 \)). This difference can be explained by the younger age of the Egyptian HF patients as compared to their European counterparts. However, when we look at the gender differences in AF in the Egyptian cohort, women had more frequent AF compared to men (34.4% vs. 22.5%, \( P < 0.001 \)). AF tended to be more frequent in the obese patients in this study (27.4 vs 25.4%) but the difference did not reach statistical significance. Several studies have demonstrated that obese patients have a 1.52 times higher risk for the development of AF compared to the normal weight population [23], and that for each point increase in BMI the frequency of new onset AF rises by 4% [24]. This relationship did not vary by age, sex, or systolic blood pressure.

**Obesity and heart failure**

**Relation of obesity to heart failure phenotype and gender**

The Framingham study investigated the risk of developing HF in obese patients [25], the study found that obese subjects had double the risk for developing HF as compared to subjects with normal BMI. For every 1 kg/m^2^ increase in BMI the, risk of HF increased by 7% in women and 5% in men. Recent studies have shown significant association between BMI and LV diastolic function, which represents the cornerstone of HFP EF [26]. Analysis of the Irbesartan in Heart Failure with Preserved Ejection Fraction trial pointed out that more two thirds of patients with HFP EF were overweight or obese [27]. The Women’s Health Study demonstrated that obesity was associated with a population attributable risk of developing HFP EF that was more than 3 times higher than that of HFrEF [28]. HFrEF was the dominant phenotype of HF in this study regardless of the BMI. However, obese patients were more likely to have a preserved LV ejection fraction than non-obese patients (22.3% vs 12.4%, \( P < 0.001 \)). We found that 31.9% of obese women had HFP EF versus 15.1% of obese men (\( P < 0.001 \)). In patients with HFP EF, 68% were classified as obese.

The mechanism of developing HF in obese patients is thought to be mediated by increased signaling through the leptin receptor, which can promote activation of both the sympathetic nervous system and the renin-angiotensin aldosterone system [29]. Additionally, adipocytes are though to cause overactivity of vasoactive peptides such as Neprilysin [29]. This cascade of interactions leads to plasma volume expansion and adverse myocyte remodeling.

**The obesity paradox**

The results of this analysis demonstrated an in-hospital survival benefit of obesity in the entire cohort of heart failure patients. However, there was no survival benefit of obesity at one-year follow-up in either sex. Even though increased BMI and obesity put patients at risk of developing cardiovascular disease (CVD), several studies have suggested that there may be an inverse relationship between obesity and the prognosis of HF—a phenomena known as the obesity paradox.

In the meta-analysis by Oreopoulos et al. of 9 observational studies including over 28,000 HF patients with a mean follow-up of 2.7 years, obesity (adjusted HR 0.88, CI [0.83–0.93]) and overweight (adjusted HR 0.93, CI [0.89–0.97]) were associated with lower mortality [30]. In contrast, a recent meta-analysis by Marcks et al. of 5,819 individual patient level data pooled from several cohorts with a mean follow-up of 5 years, showed that the “protective effect” of obesity in HF was only seen in patients older than 75 years or having at least one relevant co-morbidity, and not in younger patients with HF only [7]. Most studies that addressed the obesity paradox assessed BMI at the time of diagnosis with HF; however, in the analysis by Khalid et al. of a community-based cohort study of over 15,000 patients, BMI was evaluated at least 6 months prior to the incident date of developing HF [9], the study’s main conclusion was that patients who are overweight or obese before the diagnosis of HF had a better prognosis after they develop HF when compared with patients with normal weight. In an analysis of 3,310 patients with HFP EF where the mean follow-up was 3.4 years, abdominal obesity was associated with an approximate 50% increase in mortality after multivariable adjustment [31], and thus implying that visceral obesity pathophysiology may differ in HF patients with preserved ejection fraction as compared to those with reduced ejection fraction.

The impact of obesity on HF should be interpreted in light of a patient’s cardiorespiratory fitness (CRF). In a cohort of 774 HF patients all of whom underwent cardiorespiratory fitness testing [32], the obesity paradox was noted in patients with low exercise capacity group but not in patients who could achieve more than 4 metabolic
equivalents. The study indicated that the obesity paradox may only be applicable in HF patients with low CRF.

Multiple mechanisms have been proposed as an explanation for the obesity paradox. Obese patients may present at an earlier stage of disease as a consequence of more prominent symptoms of dyspnea associated with surplus body weight. This represents a form of lead time bias. The association between lower BMI and worse outcome may be due to advanced stage of HF and co-morbidities. Non-obese patients may lack metabolic reserve and suffer from “cardiac cachexia,” which is an established poor prognostic marker in HF. Another hypothesis is that obese patients tend to tolerate higher doses of cardioprotective HF drugs as they usually maintain a higher blood pressure. On a molecular level, obese patients have higher levels of anti-inflammatory adipokines that may neutralize circulating inflammatory endotoxins which characterizes advanced HF [33].

Despite the results of this analysis and the studies reviewed in this discussion, weight loss may be desirable in cases of HF patients with morbid obesity as it may result in improvement in exercise capacity and symptoms. The ESC recommends management of overweight and obese patients with HF as per guidelines for general CVD prevention [34]. The American Heart Association and the American College of Cardiology Heart Failure clinical practice guidelines highlight the lack of evidence on weight management in HF patients and accordingly it lacks specific recommendations [35].

Limitations
There are several limitations to this study. First, we did not include ambulatory patients with HF in the analysis, so the results of this study should not be extrapolated to patients with HF who have never been hospitalized. Second, BMI was used as the only measure of obesity and we did not have data on waist circumference, percentage of body fat or other obesity metrics. Third, only 75% of patients had 1 year follow-up data and we did not have follow-up data beyond that time. The readmission rates or quality of life measures for the enrolled patients were not captured in this registry. Finally, the diagnosis of HF was made by the treating physicians at each enrolling center’s and was not validated by a core lab based on clinical and imaging data.

Conclusions
Obesity was highly prevalent among patient admitted for decompensated HF in Egypt. Obese HF patient as compared to non-obese HF patients had higher prevalence of associated cardiometabolic disease and HFrEF phenotype on presentation. Obesity conferred a “protective effect” from in-hospital mortality, but this effect was absent at 1-year follow-up. Further studies are warranted to evaluate the effect of intentional weight loss on long-term mortality in obese HF patients.

Abbreviations
HF: Heart failure; BMI: Body mass index; EF: Ejection fraction; ESC: European Society of Cardiology; ESC-HF-LT: European Society of Cardiology Heart Failure Long-term; CKD: Chronic kidney disease; OR: Odds ratio; SBP: Systolic blood pressure; HFrEF: Heart failure with reduced ejection fraction; HFmrEF: Heart failure with mid-range ejection fraction; HFrPEF: Heart failure with preserved ejection; LV: Left ventricular; DPHS: Demographic and Health Survey; WHO: World Health Organization; NHP: National Hypertension Project; AF: Atrial fibrillation; OR: Odds ratio; I-PRESERVE: Irbesartan in Heart Failure with Preserved Ejection Fraction; CVD: Cardiovascular disease; CRF: Cardiorespiratory fitness.

Acknowledgements
We would like to express my sincere gratitude to all investigators and sub-investigators who contributed to this ESC-HF-LT registry. We would like to thank EURObservational Research Programme team for their assistance with the data set.

Authors’ contributions
AH: ran the analysis, created the tables, wrote the first draft of the manuscript. MH and MS: formulated the research question. MR: revised the manuscript. GL: revised and edited the manuscript. MSan: helped formulate the research question, edited and finalized this version of the manuscript. All authors read and approved the final manuscript.

Funding
None. The original study was funded by the European Society of Cardiology EURObservational Research Programme.

Availability of data and materials
The datasets generated and/or analysed during the current study are available on request from the European Society of Cardiology/EURObservational Research Programme.

Declarations
Ethics approval and consent to participate
The ESC-HF-LT registry was approved by each local Institutional Review Board: University of Alexandria Hospital, Garnal Abdel Nasser Insurance Hospital, Ras Eltin General Hospital, Alexandria University Students’ Hospital and International Cardiac Centre - University of Alexandria IRB; Cairo University: National Heart Institute, Dar Al Fouad and Sednawy Hospital - Cairo University IRB; Ain Shams University - Ain Shams University IRB; Zagazig University - Zagazig University IRB; Manshawiy General Hospital and Tanta University - Tanta University IRB; Damanhour General Hospital - Damanhour University IRB; Menoufeya University - Menoufeya University IRB; Benha University - Benha University IRB; Assiut University - Assiut University IRB and Beni Suef University IRB. The study complies with the Declaration of Helsinki. No data was collected before detailed information was provided to the patient, and a signed, informed consent was obtained.

Consent for publication
Given the that data set used in the analysis was de-identified no additional consent was obtained from the enrolled subjects.

Competing interests
No conflict of interest to declare.

Author details
1Westchester Medical Center/New York Medical College, Valhalla, USA. 2Alexandria University, Alexandria, Egypt. 3Ministry of Health, Cairo, Egypt.
8. Shah R, Gayat E, Januzzi JL Jr, Sato N, Cohen-Solal A, diSomma S, Fairman B, Jorge J, Hernandez AF, Liang L, Kociol RD, Krum H (2012) Patient characteristics from a randomized multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). J Card Fail 18(1):182–200

9. Khalid U, Ather S, Bavischi C, Chan W, Loehr LR, Wruuck LM, Rosamond WD, Chang PP, Coresh J, Vinri SS, Nambi V, Bozkurt B, Ballantyne CM, Deswal A (2014) Pre-morbid body mass index and mortality after incident heart failure: the ARIC Study. J Am Coll Cardiol 64(25):2743–2749

10. Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Leiro MC, Drozdz J, Erglis A, Filizbegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hadacek J, Kavoliune a, Laincak M, Logeat D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L, Heart Failure Association of the ESC (2013) Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-term Registry. Eur J Heart Fail 15(10):1173–1184

11. Hassanein M, Abdelhamid M, Ibrahim B, Elshazly A, Aboeleineen MW, Sobhy H, Nasr G, Elmeseyry F, Abdelmoniem A, Ashmawy M, Farag N, Youssef A, Elbahry Y, Sobhy M, Khairy Abdel Dayem TM, Ebed R, Reda B, Obsira H, Saleh A, Maggioni AP (2013) Clinical characteristics and management of hospitalized and ambulatory patients with heart failure—results from ESC heart failure long-term registry—Egyptian cohort. ESC Heart Fail 2(3):159–167

12. El-Zanaty F (2015) Egypt Health Issues Survey 2015. In: https://dhsprogram.com/pubs/pdf/FR315/FR315.pdf

13. Mowafi M, Khadi Z, Kawachi I, Subramanian SV, Hill A, Bennett GG (2014) Socioeconomic status and obesity in Cairo, Egypt: a heavy burden for all. J Epidemiol Global Health 4(1):113–21

14. Atsi-Selmi A, Chandola T, Friel S, Nouraei R, Shipley MJ, Marmot MG (2012) Interaction between education and household wealth on the risk of obesity in women in Egypt. PLoS ONE 7(6):e39507

15. Tackling obesity in the Eastern Mediterranean Region. EMHJ, vol. 25 No. 2 – 2019: webpage: https://apps.who.int/iris/handle/10665/272242. Accessed 12 Oct 2021

16. International Diabetes Federation. 9th edition of the IDF Diabetes Atlas. Brussels, Belgium. Website www.idf.org. Accessed 12 Oct 2021

17. Packer M, Lam CSP, Lund LH, Maurer MS, Bolhaar BA (2020) Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail 22(9):1551–1567

18. Kalogeropoulos A, Georgiopoulos V, Pitsy BM, Rodondi N, Smith AL, Harrison DG, Liu Y, Hoffmann U, Bauer DC, Newman AB, Kritchevsky SB, Harris TB, Burget J, Health ABCSI (2010) Inflammatory markers and incident heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 159(2):200–206

19. Mebazaa A (2011) Body mass index and mortality in acutely decompen-sated heart failure in 1006 Africans from 9 countries. Arch Intern Med 172(18):1386–1394

20. Ashrath JL, Hayward CS, Won Ahmad WA, Kwock R, Jorge J, Hernandez AF, Liang L, Kociol RD, Krum H (2012) Patient characteristics from a randomized multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). J Card Fail 18(1):182–200

21. Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, Burrows N, McLean A, Vilas-Boas F, Mebazaa A (2011) Clinical presentation, management and outcomes in the Acute Heart Failure Global Registry of Standard Treatment (ALARM-HF). Intensive Care Med 37(4):619–626

22. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Faris RJ, Karlson EW, Pfeffer MA, Rouleau JL, Tan-nes J, Blackshear JL, Peterson EL, Bravata DM, Rumsfeld JS, Givertz MM, Greenberg NL, Reda A, Boshra H, Saleh A, Maggioni AP (2013) Clinical characteristics and management of hospitalized and ambulatory patients with heart failure—results from ESC heart failure long-term registry—Egyptian cohort. ESC Heart Fail 2(3):159–167

23. El-Zanaty F (2015) Egypt Health Issues Survey 2015. In: https://dhsprogram.com/pubs/pdf/FR315/FR315.pdf

24. Mowafi M, Khadi Z, Kawachi I, Subramanian SV, Hill A, Bennett GG (2014) Socioeconomic status and obesity in Cairo, Egypt: a heavy burden for all. J Epidemiol Global Health 4(1):113–21

25. Atsi-Selmi A, Chandola T, Friel S, Nouraei R, Shipley MJ, Marmot MG (2012) Interaction between education and household wealth on the risk of obesity in women in Egypt. PLoS ONE 7(6):e39507

26. Tackling obesity in the Eastern Mediterranean Region. EMHJ, vol. 25 No. 2 – 2019: webpage: https://apps.who.int/iris/handle/10665/272242. Accessed 12 Oct 2021

27. Packer M, Lam CSP, Lund LH, Maurer MS, Bolhaar BA (2020) Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease. Eur J Heart Fail 22(9):1551–1567

28. Kalogeropoulos A, Georgiopoulos V, Pitsy BM, Rodondi N, Smith AL, Harrison DG, Liu Y, Hoffmann U, Bauer DC, Newman AB, Kritchevsky SB, Harris TB, Burget J, Health ABCSI (2010) Inflammatory markers and incident heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 159(2):200–206

29. Follath F, Yilmaz MB, Delgado JF, Parissis JT, Porcher R, Gayat E, Burrows N, McLean A, Vilas-Boas F, Mebazaa A (2011) Clinical presentation, management and outcomes in the Acute Heart Failure Global Registry of Standard Treatment (ALARM-HF). Intensive Care Med 37(4):619–626

30. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Faris RJ, Karlson EW, Pfeffer MA, Rouleau JL, Tan-nes J, Blackshear JL, Peterson EL, Bravata DM, Rumsfeld JS, Givertz MM, Greenberg NL, Reda A, Boshra H, Saleh A, Maggioni AP (2013) Clinical characteristics and management of hospitalized and ambulatory patients with heart failure—results from ESC heart failure long-term registry—Egyptian cohort. ESC Heart Fail 2(3):159–167

31. El-Zanaty F (2015) Egypt Health Issues Survey 2015. In: https://dhspr ogram.com/pubs/pdf/FR315/FR315.pdf

32. Mowafi M, Khadi Z, Kawachi I, Subramanian SV, Hill A, Bennett GG (2014) Socioeconomic status and obesity in Cairo, Egypt: a heavy burden for all. J Epidemiol Global Health 4(1):113–21

33. Atsi-Selmi A, Chandola T, Friel S, Nouraei R, Shipley MJ, Marmot MG (2012) Interaction between education and household wealth on the risk of obesity in women in Egypt. PLoS ONE 7(6):e39507
26. Rozenbaum Z, Topilsky Y, Khoury S, Pereg D, Laufer-Perl M (2019) Association of body mass index and diastolic function in metabolically healthy obese with preserved ejection fraction. Int J Cardiol 277:147–152
27. Haas M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE (2011) Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 4(3):324–331
28. Eaton CB, Pettinger M, Rossouw J, Martin LW, Foraker R, Quddus A, Liu S, Wampler NS, Hank Wu WC, Manson JE, Mangolis K, Johnson KC, Allison M, Corbie-Smith G, Rosamond W, Breathett K, Klein L (2016) Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multicohort of postmenopausal women. Circ Heart Fail. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002883
29. Packer M (2018) Leptin-aldosterone-neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity. Circulation 137(15):1614–1631
30. Oreopoulos A, Pachwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAllister FA (2008) Body mass index and index in heart failure: a meta-analysis. Am Heart J 156(1):13–22
31. Tsujimoto T, Kajio H (2017) Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol 70(22):2739–2749
32. McAuley PA, Keteyian SJ, Brawner CA, Dardari ZA, Al Rifai M, Ehrman JK, Al-Mallah MH, Whelton SP, Blaha MJ (2018) Exercise capacity and the obesity paradox in heart failure: the FIT (Henry ford exercise testing) project. Mayo Clin Proc 93(6):701–708
33. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD (1999) Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353(9167):1838–1842
34. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik P, Rutter FH, Schwerzer J, Seferovic P, Steppan J, Trindade PT, Voors AA, Zannad F, Zehnder A, Task Force for the D, Treatment of A, Chronic Heart Failure of the European Society of C, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knaut J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sinser PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Aperia M, Ben Lamine H, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Jung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Om S, Parisi S, Porapak S, Ponikowski P, Guidelines ESCCP (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association. Eur J Heart Fail 14(8):803–869.
35. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128(16):1810–1852

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.